These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 20462664)

  • 21. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
    Zhou H; Hu C; Zhu Y; Lu M; Liao S; Yeilding N; Davis HM
    J Clin Pharmacol; 2010 Mar; 50(3):257-67. PubMed ID: 19934030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
    Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
    Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
    Landells I; Marano C; Hsu MC; Li S; Zhu Y; Eichenfield LF; Hoeger PH; Menter A; Paller AS; Taieb A; Philipp S; Szapary P; Randazzo B
    J Am Acad Dermatol; 2015 Oct; 73(4):594-603. PubMed ID: 26259989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
    Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
    Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
    J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.
    Mrowietz U; Chouela EN; Mallbris L; Stefanidis D; Marino V; Pedersen R; Boggs RL
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1114-20. PubMed ID: 25376448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
    Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
    J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.
    Shikiar R; Bresnahan BW; Stone SP; Thompson C; Koo J; Revicki DA
    Health Qual Life Outcomes; 2003 Oct; 1():53. PubMed ID: 14613569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury.
    Ashman TA; Cantor JB; Gordon WA; Spielman L; Flanagan S; Ginsberg A; Engmann C; Egan M; Ambrose F; Greenwald B
    Arch Phys Med Rehabil; 2009 May; 90(5):733-40. PubMed ID: 19406291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions.
    Bhutani T; Patel T; Koo B; Nguyen T; Hong J; Koo J
    J Am Acad Dermatol; 2013 Aug; 69(2):e79-88. PubMed ID: 23207011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
    Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
    Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
    Tan JY; Li S; Yang K; Ma B; Chen W; Zha C; Zhang J
    J Dermatolog Treat; 2011 Dec; 22(6):323-36. PubMed ID: 20923370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.